JAK2 inhibition in murine systemic lupus erythematosus

Immunotherapy

Volumn 4, Issue 4, 2012, Pages 369-372

  Tagoe, Clement ^a   Putterman, Chaim ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

IL 6; JAK 2; lupus nephritis; plasma cells; SLE

Indexed keywords

CEP 33779; COMPLEMENT COMPONENT C3; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 6; JANUS KINASE 2 INHIBITOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CELL MATURATION; CELL POPULATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; GLOMERULONEPHRITIS; HISTOPATHOLOGY; KIDNEY; LYMPHADENOPATHY; MOUSE; NEPHRITIS; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; PLASMA CELLS; PYRIDINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRIAZOLES;

EID: 84860207018     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.20     Document Type: Article

References (12)

1. Tsokos GC. Systemic lupus erythematosus. N. Engl. J. Med. 365(22), 2110-2121 (2011).
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205-2219 (2011).
3. Lu LD, Stump KL, Wallace NH et al. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J. Immunol. 187(7), 3840-3853 (2011).
4. Wang LH, Kirken RA, Erwin RA et al. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J. Immunol. 162(7), 3897-3904 (1999). (Pubitemid 29314768)
5. Wang S, Yang N, Zhang L et al. Jak/STAT signaling is involved in the infammatory infltration of the kidneys in MRL/lpr mice. Lupus 19 (10), 1171-1180 (2010).
6. Li R, Yang N, Zhang L et al. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome. Am. J. Nephrol. 27(6), 580-589 (2007). (Pubitemid 350014945)
7. Garber K. Pfzer's JAK inhibitor sails through Phase 3 in rheumatoid arthritis. Nat. Biotechnol. 29(6), 467-468 (2011).
8. Ichikawa HT, Conley T, Muchamuel T et al. Novel proteasome inhibitors have a benefcial effect in murine lupus via the dual inhibition of type i interferon and autoantibody secreting cells. Arthritis Rheum. 64(2), 493-503 (2012).
9. Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int. Immunopharmacol. 12(1), 257-270 (2012).
10. Cash H, Relle M, Menke J et al. Interleukin 6 (IL-6) defciency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J. Rheumatol. 37(1), 60-70 (2010).
11. Illei GG, Shirota Y, Yarboro CH et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary effcacy, and impact on circulating plasma cells from an open-label Phase I dosage-escalation study. Arthritis Rheum. 62(2), 542-552 (2010).
12. Carvalho JF, Viana VS, Borba EF et al. High-titer antichromatin antibody is associated with proliferative class IV of lupus nephritis. Clin. Rheumatol. 27(11), 1417-1421 (2008).